JP5709880B2 - 血管の機能不全による進行性心筋傷害治療のための組成物および方法 - Google Patents

血管の機能不全による進行性心筋傷害治療のための組成物および方法 Download PDF

Info

Publication number
JP5709880B2
JP5709880B2 JP2012535413A JP2012535413A JP5709880B2 JP 5709880 B2 JP5709880 B2 JP 5709880B2 JP 2012535413 A JP2012535413 A JP 2012535413A JP 2012535413 A JP2012535413 A JP 2012535413A JP 5709880 B2 JP5709880 B2 JP 5709880B2
Authority
JP
Japan
Prior art keywords
months
cells
cxcr
days
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012535413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508408A5 (cg-RX-API-DMAC7.html
JP2013508408A (ja
Inventor
アンドリュー エル ペコラ
アンドリュー エル ペコラ
ロバート エイ プレティ
ロバート エイ プレティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2013508408A publication Critical patent/JP2013508408A/ja
Publication of JP2013508408A5 publication Critical patent/JP2013508408A5/ja
Application granted granted Critical
Publication of JP5709880B2 publication Critical patent/JP5709880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012535413A 2009-10-23 2010-10-22 血管の機能不全による進行性心筋傷害治療のための組成物および方法 Expired - Fee Related JP5709880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25453909P 2009-10-23 2009-10-23
US61/254,539 2009-10-23
PCT/US2010/053744 WO2011050266A1 (en) 2009-10-23 2010-10-22 Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013236030A Division JP2014037433A (ja) 2009-10-23 2013-11-14 血管の機能不全による進行性心筋傷害治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013508408A JP2013508408A (ja) 2013-03-07
JP2013508408A5 JP2013508408A5 (cg-RX-API-DMAC7.html) 2013-12-12
JP5709880B2 true JP5709880B2 (ja) 2015-04-30

Family

ID=43900703

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012535413A Expired - Fee Related JP5709880B2 (ja) 2009-10-23 2010-10-22 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2013236030A Pending JP2014037433A (ja) 2009-10-23 2013-11-14 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2015219241A Expired - Fee Related JP6761236B2 (ja) 2009-10-23 2015-11-09 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2017222587A Pending JP2018043991A (ja) 2009-10-23 2017-11-20 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2020047382A Abandoned JP2020105216A (ja) 2009-10-23 2020-03-18 血管の機能不全による進行性心筋傷害治療のための組成物および方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013236030A Pending JP2014037433A (ja) 2009-10-23 2013-11-14 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2015219241A Expired - Fee Related JP6761236B2 (ja) 2009-10-23 2015-11-09 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2017222587A Pending JP2018043991A (ja) 2009-10-23 2017-11-20 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2020047382A Abandoned JP2020105216A (ja) 2009-10-23 2020-03-18 血管の機能不全による進行性心筋傷害治療のための組成物および方法

Country Status (6)

Country Link
EP (2) EP3170891B1 (cg-RX-API-DMAC7.html)
JP (5) JP5709880B2 (cg-RX-API-DMAC7.html)
CA (1) CA2778664C (cg-RX-API-DMAC7.html)
ES (2) ES2610241T3 (cg-RX-API-DMAC7.html)
GB (1) GB2487339A (cg-RX-API-DMAC7.html)
WO (1) WO2011050266A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP5705127B2 (ja) * 2008-12-03 2015-04-22 アモーサイト インコーポレイテッド 梗塞領域灌流改善組成物および血管損傷修復の方法
CA2778664C (en) * 2009-10-23 2019-12-24 Amorcyte, Inc. Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US9533010B2 (en) 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2015073677A1 (en) * 2013-11-14 2015-05-21 The University Of Miami Non-expanded post-natal multilineage-inducible cells
US20150228115A1 (en) * 2014-02-10 2015-08-13 Kabushiki Kaisha Toshiba Medical-image processing apparatus and medical-image diagnostic apparatus
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
CN109996535B (zh) * 2016-12-28 2024-02-23 日本乐敦制药株式会社 细胞药物组合物、疾病治疗用试剂盒和细胞悬浮用溶液
JP2021521193A (ja) * 2018-04-18 2021-08-26 スンマ ヘルスＳｕｍｍａ Ｈｅａｌｔｈ 虚血および心筋症の処置のための組成物および方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520110A (en) 1981-10-06 1985-05-28 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor
US5055556A (en) 1981-10-06 1991-10-08 The Board Of Trustees Of The Leland Stanford Jr. Univ. Fluorescent conjugates for analysis of molecules and cells
CA1179942A (en) 1981-10-06 1984-12-27 Lubert Stryer Fluorescent conjugates for analysis of molecules and cells
US4859582A (en) 1981-10-06 1989-08-22 The Board Of Trustees Of The Leland Stanford Jr. University Fluorescent conjugates for analysis of molecules and cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US5656493A (en) 1985-03-28 1997-08-12 The Perkin-Elmer Corporation System for automated performance of the polymerase chain reaction
US5333675C1 (en) 1986-02-25 2001-05-01 Perkin Elmer Corp Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps
FR2596413B1 (fr) 1986-03-27 1988-06-10 Merieux Inst Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5569587A (en) 1986-04-18 1996-10-29 Carnegie Mellon University Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes
US4876190A (en) 1987-10-21 1989-10-24 Becton Dickinson & Company Peridinin-chlorophyll complex as fluorescent label
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5234824A (en) 1990-11-13 1993-08-10 Specialty Laboratories, Inc. Rapid purification of DNA
US5187083A (en) 1990-11-13 1993-02-16 Specialty Laboratories, Inc. Rapid purification of DNA
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5776709A (en) 1991-08-28 1998-07-07 Becton Dickinson And Company Method for preparation and analysis of leukocytes in whole blood
US5415636A (en) 1994-04-13 1995-05-16 Schneider (Usa) Inc Dilation-drug delivery catheter
US5968753A (en) 1994-06-14 1999-10-19 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US8075880B2 (en) 1999-01-11 2011-12-13 Steward St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for regulating angiogenesis
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7160935B2 (en) * 2003-04-04 2007-01-09 E. I. Du Pont De Nemours And Company Tubular reactor ethylene/alkyl acrylate copolymer as polymeric modifiers for asphalt
WO2006060779A2 (en) * 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
MY147516A (en) * 2005-11-07 2012-12-31 Amorcyte Inc Compositions and method of vascular injury repair cross-reference to related applications
EP2471903B1 (en) * 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
US20070190127A1 (en) * 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
JP5705127B2 (ja) * 2008-12-03 2015-04-22 アモーサイト インコーポレイテッド 梗塞領域灌流改善組成物および血管損傷修復の方法
CA2778664C (en) * 2009-10-23 2019-12-24 Amorcyte, Inc. Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2018049376A1 (en) 2016-09-12 2018-03-15 Cornell University Computational systems and methods for improving the accuracy of drug toxicity predictions

Also Published As

Publication number Publication date
EP3170891A1 (en) 2017-05-24
EP3170891B1 (en) 2020-11-25
GB2487339A (en) 2012-07-18
JP2020105216A (ja) 2020-07-09
ES2845691T3 (es) 2021-07-27
CA2778664C (en) 2019-12-24
GB201208457D0 (en) 2012-06-27
JP6761236B2 (ja) 2020-09-23
EP2491114A4 (en) 2013-11-06
JP2016029095A (ja) 2016-03-03
EP2491114A1 (en) 2012-08-29
JP2018043991A (ja) 2018-03-22
ES2610241T3 (es) 2017-04-26
WO2011050266A1 (en) 2011-04-28
EP2491114B1 (en) 2016-11-23
CA2778664A1 (en) 2011-04-28
JP2014037433A (ja) 2014-02-27
JP2013508408A (ja) 2013-03-07
EP2491114B8 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
JP5705127B2 (ja) 梗塞領域灌流改善組成物および血管損傷修復の方法
JP5709880B2 (ja) 血管の機能不全による進行性心筋傷害治療のための組成物および方法
US8088370B2 (en) Compositions and methods of vascular injury repair
US9534202B2 (en) Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US9533010B2 (en) Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US8709403B2 (en) Compositions and methods of vascular injury repair
HK1233305A1 (en) Compositions and uses for treating progressive myocardial injury due to a vascular insufficiency
HK1233305B (en) Compositions and uses for treating progressive myocardial injury due to a vascular insufficiency
HK1163542B (en) Infarct area perfusion-improving compositions and methods of vascular injury repair

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131022

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131022

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20131113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141120

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150303

R150 Certificate of patent or registration of utility model

Ref document number: 5709880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees